Insider Selling: Annexon (NASDAQ:ANNX) EVP Sells $40,149.27 in Stock

Annexon, Inc. (NASDAQ:ANNX) EVP Ted Yednock sold 7,857 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $5.11, for a total value of $40,149.27. Following the sale, the executive vice president owned 97,227 shares in the company, valued at $496,829.97. This trade represents a 7.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Annexon Trading Down 3.9%

NASDAQ ANNX opened at $4.90 on Monday. The stock has a market capitalization of $586.19 million, a price-to-earnings ratio of -3.48 and a beta of 1.17. The stock has a 50-day moving average of $5.58 and a 200 day moving average of $3.96. Annexon, Inc. has a twelve month low of $1.28 and a twelve month high of $7.18.

Annexon News Summary

Here are the key news stories impacting Annexon this week:

• Neutral Sentiment: Short-interest reports for Feb. 19–20 show 0 shares of reported short interest and a 0.0 days-to-cover metric — this appears to be a data/reporting anomaly (NaN changes). The readings do not indicate meaningful new short activity to explain the move. Short Interest Report
• Negative Sentiment: EVP Michael Overdorf sold 6,225 shares at an average $5.10 (≈$31.7k); his holdings fell ~4.8%. Form 4 – Overdorf
• Negative Sentiment: EVP Ted Yednock sold 7,857 shares at an average $5.11 (≈$40.1k); his position dropped ~7.5%. Form 4 – Yednock
• Negative Sentiment: EVP Dean Richard Artis sold 5,290 shares at an average $5.10 (≈$27.0k); his holding decreased ~4.1%. Form 4 – Artis
• Negative Sentiment: CFO Jennifer Lew sold 7,851 shares at an average $5.11 (≈$40.1k); her stake fell ~6.5%. Form 4 – Lew
• Negative Sentiment: Insider Jamie Dananberg sold 5,290 shares at an average $5.10 (≈$27.0k); his holding declined ~6.7%. Form 4 – Dananberg

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on ANNX shares. Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a research report on Wednesday, January 14th. Wells Fargo & Company upped their price target on shares of Annexon from $14.00 to $27.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 19th. Chardan Capital began coverage on Annexon in a research note on Tuesday, December 23rd. They set a “buy” rating and a $16.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Annexon in a report on Wednesday, January 21st. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $17.00.

Institutional Trading of Annexon

Large investors have recently bought and sold shares of the business. AQR Capital Management LLC lifted its stake in Annexon by 122.6% in the 1st quarter. AQR Capital Management LLC now owns 73,790 shares of the company’s stock worth $142,000 after purchasing an additional 40,637 shares in the last quarter. Jane Street Group LLC increased its holdings in shares of Annexon by 8.2% in the first quarter. Jane Street Group LLC now owns 99,924 shares of the company’s stock valued at $193,000 after purchasing an additional 7,553 shares during the last quarter. Acadian Asset Management LLC increased its holdings in shares of Annexon by 31.1% in the first quarter. Acadian Asset Management LLC now owns 203,990 shares of the company’s stock valued at $393,000 after purchasing an additional 48,345 shares during the last quarter. Vanguard Personalized Indexing Management LLC purchased a new position in Annexon during the second quarter worth approximately $29,000. Finally, CWM LLC boosted its stake in Annexon by 212.9% during the second quarter. CWM LLC now owns 17,734 shares of the company’s stock worth $43,000 after buying an additional 12,066 shares during the last quarter.

Annexon Company Profile

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.